PHIO: מזומנים למניה Phio Pharmaceuticals Corp

Phio Pharmaceuticals (PHIO) is expanding its oncology portfolio by suppressing tumor genes via RNA interference. This cash per share chart clearly demonstrates financial stability, where the 0.87 level captures the current state. This reinforces the pricing power of the INTASYL platform, which creates self-delivering RNA strands. The company is currently actively developing immuno-oncology products to enhance T-cells for the fight against cancer.
פילוחי מדדים מקיפים ואנליטיקה עבור RXi Pharmaceuticals (PHIO)

Investors are assessing fundamental risks by analyzing available liquidity per unit of capital. For Phio Pharmaceuticals (PHIO), maintaining a cash reserve for the development of the INTASYL platform and the conduct of clinical trials is critical. The cash per share metric reflects the current volume of cash reserves distributed among all shareholders. A downward trend on this chart signals intensive capital burn. A stable metric level confirms the company's financial stability until new strategic investments are secured.